Haemonetics
NYSE:HAE Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
WA
Consensus Narrative from 10 Analysts
VASCADE MVP XL Device Launch Will Expand Interventional Technology Market
Key Takeaways New technology investments in plasma collection and hospital markets expected to drive short and long-term profitable growth and increase market share. Expansion in interventional and hospital products to global markets is set to boost revenue, margins, and utilization rates.
View narrativeUS$110.80
FV
42.2% undervalued intrinsic discount7.47%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
21 days ago author updated this narrative